In vitro activity of AVE1330A, an innovative broad-spectrum non- -lactam -lactamase inhibitor

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1The inhibition of class C β -lactamases by boronic acids1983 · 159 citations
2. 2Outcome of Cephalosporin Treatment for Serious Infections Due to Apparently Susceptible Organisms Producing Extended-Spectrum β-Lactamases: Implications for the Clinical Microbiology Laboratory2001 · 548 citations
3. 3Variations in the Prevalence of Strains Expressing an Extended‐Spectrum β‐Lactamase Phenotype and Characterization of Isolates from Europe, the Americas, and the Western Pacific Region2001 · 441 citations
4. 4Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat2001 · 2,643 citations
5. 5Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Community and Private Health Care Centers2003 · 156 citations